WAYNE, Pa., April 19 /PRNewswire-FirstCall/ -- Encorium Group, Inc. , a full service multinational clinical research organization (CRO) conducting studies in over 30 countries for many of the world's leading pharmaceutical and biotechnology companies, today announced its financial results for the fourth quarter and year ended December 31, 2009.
As previously announced, on July 16, 2009 the Company sold substantially all of the assets relating to its U.S. line of business to Pierrel Research USA, Inc., the result of which the Company no longer has any employees or significant operations in the United States. Due to this sale, for the three and 12 months ended December 31, 2009 and 2008, the results of the U.S. business have been presented as discontinued operations in the Company's consolidated financial statements.
2009 Fourth Quarter Financial Results
Net revenue for the fourth quarter of 2009 was $4.4 million, a decrease of 21.4% from $5.6 million for the fourth quarter of 2008. The decrease in net revenues was primarily attributable to overall reductions in clinical trial activity, approximately $491 thousand of revenue recognized on contracts that completed in 2008 off set by favorable foreign currency fluctuations of $480 thousand for the three months ended December 31, 2009. The Company had a consolidated backlog at December 31, 2009 from continuing operations of $17.1 million which included approximately $12.3 million of new business wins in 2009 compared to a backlog of $23.8 million at December 31, 2008.
Direct expenses for the fourth quarter of 2009 were $3.3 million, or 74.9% of net revenues, compared to $3.6 million, or 64.4% of net revenues, for the comparable prior year period. The decrease in direct expenses was primarily the result of reductions in staff and subcontractors utilized on active clinical studies being conducted and approximately $341 thousand of unfavorable foreign currency fluctuation.
Selling, general, and administrative expenses (SG&A) was $1.7 million, or 38.5% of net revenue, for the three months ended December 31, 2009, compared to $2.2 million, or 39.2% of net revenue, for the three months ended December 31, 2008.
Loss from continuing operations decreased to $558 thousand or $(0.18) per diluted share for the fourth quarter of 2009, from a net loss of $12.6 million, or $(4.92) per diluted share, in the fourth quarter of 2008.
2009 Full Year Financial Results
Net revenue for the twelve months ended December 31, 2009 decreased to $17.9 million as compared to $22.3 million for the twelve months ended December 31, 2008. The decrease in revenue was primarily due to a decrease in the number of contracts and related contract values of active clinical studies along with $1.1 million of unfavorable currency fluctuations.
Direct expenses for the year ended December 31, 2009 were $12.6 million compared to $14.6 million for the year ended December 31, 2008. Despite reduced staffing and subcontractor costs and a favorable currency fluctuation of $1.1 million, direct expenses as a percent of net revenue increased to 70.3% from 65.6% in the prior year due to lower net revenues. SG&A expenses for 2009 were $8.1 million, or 45.4% of net revenue, compared to $9.0 million, or 40.5% of net revenue, for 2008. Of the $916 thousand decrease in SG&A, approximately $581 thousand was attributable to favorable foreign currency fluctuations, with the remainder a result of reductions in staff and overhead.
Depreciation and amortization expense for 2009 declined to $380 thousand compared to $1.3 million for 2008, primarily as a result of intangibles related to the Encorium OY acquisition becoming fully amortized.
The Company reported a net loss from continuing operations for the twelve months ended December 31, 2009 of $3.1 million, or $(1.16) per diluted share, as compared to a net loss from continuing operations of $16.9 million, or $(6.57) per diluted share for the twelve months ended December 31, 2008. Included in the 2008 results is a non-cash $14.4 million, or ($0.70) per share, asset impairment charge related to the Company's intangible assets, which includes a $1.9 million non-cash interim asset impairment charge recorded by the Company during the third quarter of 2008 as well as the $12.5 million charge taken in the fourth quarter.
Financial Position, Going Concern and Potential Delisting
Encorium's balance sheet at December 31, 2009 reflected cash and cash equivalents of $197 thousand and stockholders' equity of $2.3 million. Our net cash used in operations for the year ended December 31, 2009 was approximately $8.0 million. The Company's latest financials have been prepared on a going concern basis. The report of Encorium's independent registered public accounting firm, included in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 19, 2010, contains a paragraph that indicates that, while the Company's financial statements have been prepared on a going concern basis, there is substantial doubt about its ability to continue as a going concern, and that no adjustments have been made to the financial statements that might result from the outcome of this uncertainty.
We anticipate that will meet our cash requirements at least into March of 2011, assuming we are able to fully implement our current costs cutting initiatives, we are able to win additional contracts and we are able to maintain our current customer contracts. In the event we are unable to do so, in order for the Company to continue as a going concern we will be required to obtain additional capital from external sources or significantly reduce our operating costs, which may include the cessation of operations in some countries.
Encorium currently fails to meet NASDAQ's $2.5 million minimum stockholders' equity requirement for continued listing and may not be able to meet the other listing requirements in the future. The Company anticipates that a delisting action will be brought against it for failure to comply with the requirement. If a delisting action is brought, the Company may request a hearing before the NASDAQ Listing Qualifications Panel. Such request would stay any delisting determination by the NASDAQ Listing Qualifications Staff and the Company's common stock would remain listed on NASDAQ pending a formal determination by the Panel. However, there can be no assurances that the Panel will grant such request.
Dr. Kai Lindevall, executive chairman stated, "We are very pleased with the cost cutting initiatives that we have put in place. While additional financing is likely necessary, we believe our experience and capabilities in the vaccine field coupled with the recent new awards in this area demonstrate the long term potential we have to grow into a leading vaccine franchise with expertise in regulatory consultancy and strategic trial planning."
About Encorium Group, Inc.
Encorium Group, Inc. is a global clinical research organization specializing in the design and management of complex clinical trials and Patient Registries for the pharmaceutical, biotechnology and medical device industries. The Company's mission is to provide its clients with high quality, full-service support for their biopharmaceutical and medical device development programs. Encorium offers therapeutic expertise, experienced team management and advanced technologies. The Company has drug and biologics development as well as clinical trial experience across a wide variety of therapeutic areas such as infectious diseases, cardiovascular, vaccines, oncology, diabetes endocrinology/metabolism, gene therapy, immunology, neurology, gastroenterology, dermatology, hepatology, women's health and respiratory medicine. Encorium believes that its expertise in the design of complex clinical trials, its therapeutic experience and commitment to excellence, and its application of innovative technologies, offer its clients a means to more quickly and cost effectively move products through the clinical development process.
This press release contains forward-looking statements identified by words such as "estimate," "project," "expect," "intend," "believe," "anticipate" and similar expressions. Those statements involve risks and uncertainties, and actual results could differ materially from those discussed. Factors that could cause or contribute to such differences include, but are not limited to: (i) the risk that we may not have sufficient funds to operate our business; (ii) our success in attracting new business and retaining existing clients and projects; (iii) the size, duration and timing of clinical trials we are currently managing may change unexpectedly; (iv) the termination, delay or cancellation of clinical trials we are currently managing could cause revenues and cash-on-hand to decline unexpectedly; (v) the timing difference between our receipt of contract milestone or scheduled payments and our incurring costs to manage these trials; (vi) outsourcing trends in the pharmaceutical, biotechnology industries; (vii) the ability to maintain profit margins in a competitive marketplace; (viii) our ability to attract and retain qualified personnel; (ix) the sensitivity of our business to general economic conditions; (x) other economic, competitive, governmental and technological factors affecting our operations, markets, products, services and prices; (xi) announced awards received from existing and potential customers are not definitive until fully negotiated contracts are executed by the parties; (xii) our backlog may not be indicative of future results and may not generate the revenues expected; (xiii) uncertainties regarding the availability of additional capital; and (xiv) uncertainties regarding the continued listing of our common stock on NASDAQ. You should not place undue reliance on any forward-looking statement. We undertake no obligation to publicly release the result of any revision of these forward-looking statements to reflect events or circumstances after the date they are made or to reflect the occurrence of unanticipated events. Please refer to the section entitled "Risk Factors" in the Company Annual Report on Form 10-K for the year ended December 31, 2009 for a more complete discussion of factors which could cause our actual results and financial position to change.
--financial tables to follow-- ENCORIUM GROUP, INC CONSOLIDATED STATEMENTS OF OPERATIONS Three Months Ended December 31, 2009 2008 ---- ---- Revenue Net revenue $4,389,075 $5,581,974 Reimbursement revenue 733,016 972,670 Total Revenue 5,122,091 6,554,644 --------- --------- Operating Expenses Direct 3,285,797 3,592,637 Reimbursement out-of-pocket expenses 733,016 972,670 Selling, general and administrative 1,688,937 2,187,486 Depreciation and amortization 98,192 98,997 Impairment loss - 12,535,809 --- ---------- Total Operating Expenses 5,805,942 19,387,599 --------- ---------- Loss from Operations (683,851) (12,832,955) Interest Income 14,271 16,409 Interest Expense (24,356) 3,732 ------- ----- Net Interest (Expense) Income (10,085) 20,141 Other expense - - Net Loss from continuing operations before Income Taxes (693,936) (12,812,814) -------- ----------- Income Tax Expense (Benefit) (136,035) (163,940) -------- -------- Net Loss from continuing operations $(557,901) $(12,648,874) ========= ============ Net loss from discontinued operations (171,250) (1,090,418) Income Tax Expense (Benefit) - - --- --- Net Loss $(729,151) $(13,739,293) ========= ============ Weighted Average Common and Common Equivalent Shares Outstanding Basic 3,138,713 2,575,651 Diluted 3,138,713 2,575,651 Net Loss per Common Share Continuing Operations $(0.18) $(4.92) Discontinued Operations $(0.05) $(0.42) ------ ------ Net Loss per Common Share $(0.23) $(5.34) ====== ====== Years Ended December 31, 2009 2008 ---- ---- Revenue Net revenue $17,857,117 $22,298,938 Reimbursement revenue 3,309,558 4,058,224 Total Revenue 21,166,675 26,357,162 ---------- ---------- Operating Expenses Direct 12,556,650 14,619,463 Reimbursement out-of-pocket expenses 3,309,558 4,058,224 Selling, general and administrative 8,068,683 9,023,951 Depreciation and amortization 380,130 1,282,678 Impairment loss - 14,391,992 --- ---------- Total Operating Expenses 24,315,021 43,376,308 ---------- ---------- Loss from Operations (3,148,346) (17,019,146) Interest Income 9,315 30,165 Interest Expense (50,532) (20,312) ------- ------- Net Interest (Expense) Income (41,217) 9,853 Other expense - - Net Loss from continuing operations before Income Taxes (3,189,563) (17,009,293) ---------- ----------- Income Tax Expense (Benefit) (45,136) (103,671) ------- -------- Net Loss from continuing operations $(3,144,427) $(16,905,622) =========== ============ Net loss from discontinued operations (725,266) (4,167,854) Income Tax Expense (Benefit) - - --- --- Net Loss $(3,869,693) $(21,073,476) =========== ============ Weighted Average Common and Common Equivalent Shares Outstanding Basic 2,709,904 2,575,651 Diluted 2,709,904 2,575,651 Net Loss per Common Share Continuing Operations $(1.16) $(6.57) Discontinued Operations $(0.27) $(1.62) ------ ------ Net Loss per Common Share $(1.43) $(8.19) ====== ====== ENCORIUM GROUP, INC CONSOLIDATED BALANCE SHEET (UNAUDITED) December 31, 2009 2008 ---- ---- Assets Current Assets Cash and cash equivalents $196,583 $5,705,818 Investigator advances 19,232 11,971 Accounts receivable, less allowance of $412,973 and $97,000 for December 31, 2009 and 2008, respectively 3,454,173 3,253,617 Prepaid expenses and other 872,722 956,378 Prepaid taxes 0 - Costs and estimated earnings in excess of related billings on uncompleted contracts 1,794,134 606,260 Debt issuance costs, current 75,400 Current assets of discontinued operations 28,832 3,562,508 ------ --------- Total Current Assets 6,441,076 14,096,552 --------- ---------- Property and Equipment, Net 307,552 330,263 Intangible Assets Goodwill 1,389,045 1,366,269 Other intangibles, Net 3,508,310 3,733,517 Debt issuance costs, long- term 150,800 Other assets 313,524 349,357 Long-term assets of discontinued operations - 1,216,975 Total Assets $12,110,307 $21,092,933 =========== =========== Liabilities and Stockholders' Equity Current Liabilities Accounts payable $1,756,678 $2,429,339 Note payable 334,413 - Credit Line 300,697 - Accrued expenses 2,333,099 2,719,187 Deferred taxes 248,117 206,173 Obligations under capital leases 54,510 44,097 Billings in excess of related costs and estimated earnings on uncompleted contracts 1,179,779 1,262,661 Customer advances 1,361,496 2,344,486 Current liabilities of discontinued operations 607,552 6,505,817 ------- --------- Total Current Liabilities 8,176,341 15,511,760 --------- ---------- Long Term Liabilities Notes Payable 668,826 - Obligations under capital leases 52,541 100,402 Deferred taxes 837,424 897,204 Other liabilities 104,624 200,175 Long-term liabilities of discontinued operations - 205,619 --- ------- Total Long Term Liabilities 1,663,415 1,403,400 --------- --------- Total Liabilities 9,839,756 16,915,160 --------- ---------- Stockholders' Equity Common stock, $.001 par value 4,375,000 shares authorized, 3,426,938 and 2,604,25 shares issued at December 31, 2009 and 2008 and 3,388,173 and 2,565,486 shares outstanding at December 31, 2009 and 2008, respectively 3,427 2,604 Additional paid-in capital 35,142,854 32,435,480 Additional paid-in capital warrants 299,606 905,699 Accumulated deficit (33,607,123) (29,737,430) Accumulated other comprehensive income 1,158,476 1,298,109 --------- --------- Less: 2,997,240 4,904,462 Treasury stock, at cost, 38,765 shares (726,689) (726,689) -------- -------- Total Stockholders' Equity 2,270,551 4,177,773 --------- --------- Total Liabilities and Stockholders' Equity $12,110,307 $21,092,933 =========== =========== See accompanying notes to the consolidated financial statements.
Encorium Group, Inc.
CONTACT: Philip L. Calamia, Chief Financial Officer, Encorium Group,
Inc., +1-484-588-5400, http://www.encorium.com/
Web Site: http://www.encorium.com/
